Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-11-30-Speech-4-018"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20061130.4.4-018"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"The availability of antiretroviral therapy does not just bring hope to AIDS sufferers themselves. It also transforms attitudes to AIDS in the wider population. The knowledge that effective treatment is available is a key factor in encouraging people to be tested for HIV. The more people are aware of their HIV status, the easier it is to control the spread of the disease.
That is why it is particularly worrying that the price of new, improved and second-line AIDS medicines remains prohibitively high. It is good news that the price of some established first-line AIDS drugs has come right down, but figures from South Africa and Malawi indicate that up to one in six patients will need to switch to newer drug combinations within three to five years.
What can the Commission do to persuade pharmaceutical companies to register their newer drugs in developing countries and make those newer drugs available at affordable prices? Failing that, we will soon be back to square one. The drugs that still work will be unaffordable and donors, including the EU, will effectively be donating to the pharmaceutical industry."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples